Clinical Trial Update: De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia [Phase 2]

View source ↗

Summary

This Phase 2 trial examines de-escalation and stopping treatment with imatinib, nilotinib, or dasatinib (Sprycel) in chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Sprycel (dasatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: University of Liverpool | Conditions: Chronic Myeloid Leukaemia | Phase 2 | Status: COMPLETED